191,577 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC acquired a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 191,577 shares of the biopharmaceutical company’s stock, valued at approximately $1,831,000. Allspring Global Investments Holdings LLC owned 0.35% of Emergent BioSolutions at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EBS. Stifel Financial Corp purchased a new stake in Emergent BioSolutions in the 3rd quarter worth about $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $103,000. Landscape Capital Management L.L.C. purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $141,000. Entropy Technologies LP purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $155,000. Finally, PFG Investments LLC purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $228,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EBS has been the topic of several research reports. Benchmark lifted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st.

Emergent BioSolutions Stock Down 1.3 %

EBS stock opened at $7.74 on Friday. The stock has a market capitalization of $419.44 million, a P/E ratio of -1.89 and a beta of 1.62. The firm has a 50-day simple moving average of $9.66 and a 200-day simple moving average of $9.07. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52 week low of $1.82 and a 52 week high of $15.10.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.